> there are thousands of papers demonstrating preclinical utility of nanoparticles for many applications, and extremely few actual medicines.
For nanoparticle delivered mRNA, things are relatively early and relatively little is to market. But I don't think we can reasonably dismiss it as being niche or not too useful, given that we just dosed hundreds of millions of people for the biggest emergent public health issue in recent memory.
For nanoparticle delivered mRNA, things are relatively early and relatively little is to market. But I don't think we can reasonably dismiss it as being niche or not too useful, given that we just dosed hundreds of millions of people for the biggest emergent public health issue in recent memory.